Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

Mural Oncology (NASDAQ:MURA), which was spun out of Irish biotech Alkermes (NASDAQ:ALKS) in 2023, lost ~47% in the premarket ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing ...

Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Nearly half of women diagnosed with ovarian cancer are not receiving the genetic testing that could help guide treatment and improve outcomes, according to a new analysis from Ovarian Cancer Research ...

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

In a study on ovarian cancer cells, researchers from Karolinska Institutet demonstrate how the tumor environment influences ...